Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AYX-301
- Development stage
- Preclinical
- Lead developer
- Ayma Therapeutics
- Modality
- Cell Therapies, Nanoparticles → Drug Delivery Systems
01
Overview
AYX-301 is an investigational **TCNP encapsulated red cell therapy** being developed by **Ayma Therapeutics** for **lymphangioleiomyomatosis**. The program uses Ayma's red blood cell encapsulation and transcellular nanoparticle platform to deliver an undisclosed therapeutic payload with the goal of sustained and potentially targeted delivery; company materials indicate it is intended for use in combination with **sirolimus** in LAM. The precise molecular target and payload have not been publicly disclosed, and the available pipeline information is most consistent with an early **preclinical** development-stage product.
- Other names
- TCNP encapsulated red cell therapy
Beyond the preview
Go deeper on AYX-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AYX-301.